| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H33ClO5 |
| Molecular Weight | 448.98 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])C=C(Cl)C4=C[C@H](CC[C@]34C)OC(C)=O
InChI
InChIKey=KSCZWFXQKITHSL-OKCNGXCSSA-N
InChI=1S/C25H33ClO5/c1-14(27)25(31-16(3)29)11-8-20-18-13-22(26)21-12-17(30-15(2)28)6-9-23(21,4)19(18)7-10-24(20,25)5/h12-13,17-20H,6-11H2,1-5H3/t17-,18+,19-,20-,23+,24-,25-/m0/s1
| Molecular Formula | C25H33ClO5 |
| Molecular Weight | 448.98 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Patents
Sample Use Guides
Clogestone Acetate (AY-11440) was tested at several doses for 3 cycles in 14 postmenopausal women and 7 ovulating women. Patients and doses were the following: 14 postmenopausal women with vasomotor syndrome who were given 1.25 mg Premarin for 21 days and .1 mg, 1 mg, or 3 mg AY-11440, for the last 10 days of a cycle; and 7 cycling women seeking contraception, given .1, .5, or 1 mg AY-11440 daily from Day 5-25.
Route of Administration:
Oral
